What we are readingThe Reading Room.
Stories worth sitting with, and a pathologist’s take on why they matter. Follow through to the original writers for their full work.
Explore recommended links →
BESSEMER VENTURE PARTNERS + BAIN & COMPANY · SEPTEMBER 30, 2026A 2026 survey of 226 healthcare executives across 65 AI use cases reports that returns arrived sooner than expected: roughly 12 months rather than the 24 months buyers had planned for, with an average return of 3.5 times the cost. The strongest returns are concentrated in administrative work. Revenue cycle management leads at 4.0x; provider clinical use cases report 2.9x. Semi- or fully autonomous agents account for 67% of provider revenue-cycle solutions, compared with 4% in clinical work.
Read the pathologist's take →THE LANCET 2024 + JCO 2026Personalized mRNA after melanoma surgery, alongside Keytruda. The five-year phase 2b data and the new phase 3 topline, with the limits kept in view.
Read the paper and the pathologist's take →CLEVELAND CLINIC · AUGUST 28, 2026One infusion and a durable lipid signal in a 15-person first-in-human study. A promising start, not proof of fewer heart attacks.
Read the pathologist's take →
STAT · September 16, 2026A pathology professor teaches cancer with his own biopsy and experience as a patient.
Read the pathologist's take →XACT ROBOTICSWhy getting the right lung biopsy material starts before the slide, and what a moving-target robotic system may contribute.
Read the pathologist's take → 